Pharmacoeconomic review report: Brexpiprazole (Rexulti) (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults
Brexpiprazole (Rexulti) is an oral atypical antipsychotic (AAP) drug indicated for the treatment of schizophrenia in adults. It is available as a 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg tablet at a flat price of .50 per tablet, or .50 per day at the recommended dosage of 2 mg to 4 mg daily. Acco...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
[Ottawa Ontario]
Canadian Agency for Drugs and Technologies in Health
2017, December 2017
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Brexpiprazole (Rexulti) is an oral atypical antipsychotic (AAP) drug indicated for the treatment of schizophrenia in adults. It is available as a 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg tablet at a flat price of .50 per tablet, or .50 per day at the recommended dosage of 2 mg to 4 mg daily. According to the product monograph for brexpiprazole, a starting dosage of 1 mg daily is recommended on days 1 to 4, followed by titration to a 2 mg daily dosage on days 5 to 7; daily dose may be increased to 4 mg on day 8 according to the patient's clinical response and tolerability. The maximum recommended daily dose is 4 mg for most patients. The manufacturer is seeking reimbursement of brexpiprazole for the treatment of schizophrenia in adults, as per the Health Canada- approved indication |
|---|---|
| Item Description: | "Version: final (with redactions)." |
| Physical Description: | 1 PDF file (15 pages) |